Listen to this episode of Longevity by Design on Apple Podcasts, Spotify, and YouTube.
Dr. Gil Blander welcomes Dr. Daniel Durand, Chief Medical Officer at Prenuvo, to Longevity by Design for a deep dive into the future of preventative healthcare. Dr. Durand shares how full-body MRI is redefining early detection by making advanced imaging accessible, non-invasive, and radiation-free. He explains why MRI, as a soft tissue imaging modality, offers unmatched insight into early-stage cancers and chronic conditions.
The conversation unpacks misconceptions around overdiagnosis and false positives, challenging the idea that “not knowing” is safer. Dr. Durand outlines how AI-enhanced imaging, paired with structured follow-up care, reduces unnecessary biopsies and improves diagnostic accuracy. He also discusses the emotional and systemic costs and benefits of proactive screening.
Looking ahead, Dr. Durand envisions a healthcare model built on data, personalization, and patient empowerment. He argues that gathering better information, earlier, will shift the focus from treatment to prevention and help more people maintain peak health for longer.
Guest-at-a-Glance
💡 Name: Dr. Daniel Durand
💡What he does: Chief Medical Officer
💡Company: Prenuvo
💡Noteworthy: Leader in radiology innovation and early detection through full-body MRI.
💡 Where to find him: LinkedIn
Episode highlights:
Introduction to MRI and Its Advancements 00:00:00
Welcome and Guest Introduction 00:00:59
Dr. Durand's Career Journey 00:02:07
Choosing Radiology and MRI 00:03:09
The Future of Radiology and AI 00:04:48
Early Detection and Preventative Health 00:11:21
The Patient Experience at Pvo 00:29:27
Capabilities and Benefits of MRI 00:35:47
Liquid Biopsy vs. Whole Body MRI 00:44:00
Combining Diagnostic Methods 00:46:31
Colonoscopy and MRI: Complementary Tools 00:48:30
Risks and Benefits of Full Body MRI 00:51:28
Addressing Concerns and Criticisms 00:54:37
Patient Empowerment and the Future of Diagnostics 00:55:44
Emotional Impact of Diagnostic Information 00:57:00
Consultation and Communication with Patients 01:01:14
Technological Innovations in MRI 01:05:07
Target Audience for Full Body MRI 01:10:52
Future of Healthspan and Longevity 01:16:18
Key Insights
Full-Body MRI Is Changing the Rules of Early Detection
Dr. Durand explains why full-body MRI, particularly without contrast or radiation, is becoming a powerful tool for early detection of cancer and other chronic diseases. Unlike conventional methods that rely on symptoms or limited screenings, MRI can visualize soft tissue changes across multiple organ systems simultaneously. This technology extracts over a billion data points in 40 minutes, offering a panoramic view of a patient’s internal health. He emphasizes that while MRI isn’t diagnostic on its own, it flags abnormalities for follow-up. The goal isn’t to replace traditional screenings like colonoscopies or mammograms but to add a layer of proactive insight that can lead to earlier intervention and better outcomes.
Radiologists Won’t Be Replaced—Their Roles Will Evolve
Despite predictions that AI will replace radiologists, Dr. Durand argues their role is shifting, not disappearing. Radiology, as one of the first fully digital specialties, is already transforming machine learning and automation. AI can handle much of the pattern recognition and high-volume image review, allowing radiologists to focus on more nuanced tasks, like synthesis, clinical collaboration, and patient communication. He compares it to what happened with accountants after TurboTax: the field expanded, wages rose, and job satisfaction improved. In the future, radiologists may spend less time reading plain films and more time acting as strategic diagnosticians within care teams.
Early Detection Works—Even If It’s Hard to Prove
Dr. Durand addresses a common critique of early detection: that it doesn’t always extend life. He points out that while long-term randomized studies are scarce, because they’re difficult and time-consuming to run, the clinical logic remains sound. In populations with genetic or environmental risk factors, full-body MRI has already demonstrated value in detecting cancers earlier, when they are most treatable. He also challenges the idea that some cancers are “better left undiscovered,” calling that view ethically and clinically flawed. Durand insists that empowering patients with accurate, early information is preferable to reactive care, even if not all benefits are statistically quantifiable yet.
MRI and Liquid Biopsy Are Complementary, Not Competitive
As new technologies like liquid biopsies gain attention, Dr. Durand emphasizes that full-body MRI and blood-based cancer screening are not competing—they’re synergistic. Liquid biopsy excels at detecting blood cancers like leukemia and lymphoma, while MRI is better at catching solid tumors in deep tissue before they metastasize. Together, they increase confidence in results. A double negative provides strong reassurance; a double positive signals urgency. What’s unclear, but worth studying is how to interpret mixed signals between the two. Dr. Durand advocates for ongoing research and integration of both tools into long-term personalized health strategies, especially for at-risk individuals.
MRI as the Entry Point to a New Healthcare Model
Dr. Durand outlines how he is flipping the traditional diagnostic model by placing MRI at the front of the healthcare journey instead of the back. He explains how MRI, combined with patient-friendly experiences and structured data capture, can shift the healthcare paradigm from reactive to proactive. This approach is especially valuable in bringing patients into the system earlier, many of whom previously had no regular care or primary physician.
"If you can engage a patient and you can give them a good experience and grab a massive amount of their data and then make it relevant to them early on in the health trajectory, there is just no way that you are not gonna produce massive healthcare value, both for the patient, honestly, and for society."
From Hopkins to Prenuvo: A Career Shaped by Data and Access
Dr. Durand walks through his career path from Johns Hopkins to his role as CMO at Prenuvo. His background spans academic research, healthcare system leadership, consulting at McKinsey, and implementing AI at scale. These experiences shaped his view that structural change, especially around accessibility to imaging and early diagnostics, must go hand-in-hand with tech innovation. He saw MRI as a practical, scalable tool for empowering patients and improving outcomes.
"I can continue to kind of rearrange the deck chairs on the Queen Mary here... or I can do something really different and take a risk... I decided to let go of the sunk cost bias of a very comfortable position and come over to a less comfortable but more ambitious group of people."
For science-backed ways to live a healthier longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast
Similar Longevity By Design episodes we think you would love:
- The Latest Updates in Longevity Research with Dr. Eric Verdin
- Dr. Andrea Maier—Mechanisms of Aging
- XPRIZE Healthspan: Revolutionizing Human Aging & Healthspan with Dr. Jamie Justice
